anti-CD19 FasT CAR-T cells

Developed for: B-cell non-Hodgkin lymphoma
Investigated by: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China · Chongqing University Cancer Hospital · Gracell Biotechnologies (Shanghai) Co., Ltd. · The Affiliated Hospital Of Guizhou Medical University · The Second Affiliated Hospital of Chongqing Medical University · The Second Affiliated Hospital of Kunming Medical University
+1 more
· Xinqiao Hospital of Chongqing

today NCT04638270 · Ph 0

202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 0	NCT04638270	Nov 2020 → Nov 2021	B-cell non-Hodgkin lymphoma	Xinqiao Hospital of Chongqing	Unknown	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	anti-CD19 FasT CAR-T cells	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04638270 ↗
Modality	Cell therapy	“FasT CAR-T cells” NCT04638270 ↗
Target	CD19	“CD19 targeted CAR-T cells” NCT04638270 ↗